Point72 Asset Management, L.P. Adds $26M in Beta Bionics, Inc. ($BBNX)
The firm significantly boosted its investment in Beta Bionics, reflecting a strong vote of confidence.
Key Points
- Point72 Asset Management increased its position in Beta Bionics by 156%, adding 1,537,689 shares to hold a total of 2,525,040 shares valued at $40.17 million.
- Shares of Beta Bionics, trading on the NasdaqGM under the ticker BBNX, were priced at $15.91 on Friday, with a market cap around $709 million and no meaningful P/E ratio due to negative earnings.
- Analysts maintain a positive outlook, with Goldman Sachs, B of A Securities, and others setting price targets between $11 and $24.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Point72 Asset Management has significantly increased its stake in Beta Bionics, Inc. (NasdaqGM: BBNX), according to the latest Form 13F filing with the SEC. The firm boosted its holdings by 1,537,689 shares, a 155.7% increase, bringing its total to 2,525,040 shares. The value of this position is approximately $40.17 million, as of the reporting period.
Point72 Asset Management, L.P. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Point72's Beta Bionics Position
Point72 Asset Management added 1,537,689 shares to its Beta Bionics holdings, marking a 155.7% increase from its previous count of 987,351 shares. This significant addition brings the firm's total to 2,525,040 shares, valued at about $40.17 million.
Other Institutional Activity in Beta Bionics
Other institutional investors also adjusted their positions in Beta Bionics. Eventide Asset Management grew its holdings by 950,760 shares, ending with 5,945,488 shares worth around $59.57 million. Soleus Capital Management increased its stake by 1,819,936 shares, now holding 4,354,501 shares valued at $43.63 million. Morgan Stanley added 768,181 shares to reach a total of 4,227,634 shares, valued at approximately $42.36 million. Conversely, Farallon Capital Management reduced its holdings by 706,000 shares, resulting in 3,607,920 shares valued at $36.15 million.
Beta Bionics, Inc. Stock Down 13.8%
Shares of Beta Bionics traded near $15.91 on Friday. The company, which specializes in medical devices, has a market cap of about $709 million. It currently lacks a meaningful P/E ratio due to negative earnings, with an EPS of -$1.37. The stock's 52-week range is between $8.80 and $32.71, with a 50-day moving average of $11.95 and a 200-day moving average of $18.34. The company's current ratio stands at 10.69, indicating strong liquidity.
$BBNX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Beta Bionics reported revenue of $110.24 million, showing a growth rate of 56.6%. However, the company posted a net margin of -60.3% and a return on equity of -22.7%. The next earnings report is expected on July 21, 2026.
Analysts Set New Price Targets
Analysts have maintained their ratings on Beta Bionics with several firms setting various price targets. On May 27, 2026, Goldman Sachs maintained a 'buy' rating with a $17 price target. B of A Securities also maintained a 'hold' rating with an $11 target on May 18, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price of $19.18 based on 11 opinions.
About Beta Bionics
Beta Bionics, Inc. is a healthcare company based in Irvine, California. It focuses on developing medical devices to improve the lives of people with diabetes. The company offers the iLet Bionic Pancreas, an insulin delivery device, and is working on other innovative solutions like the Patch Pump and Bihormonal iLet. Led by CEO Sean T. Saint, Beta Bionics employs around 420 people and collaborates with partners like Xeris Pharmaceuticals and Abbott Diabetes Care.
Bottom Line
Point72 Asset Management's substantial increase in Beta Bionics shares highlights growing institutional interest in the company. While the 13F filing reflects past holdings and not necessarily current positions, it indicates confidence in Beta Bionics' potential. Investors will watch for the upcoming earnings report and any changes in analyst ratings for further insights.
Get Beta Bionics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BBNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.